as well as other ranitidine products sold by other companies – increased the risk of cancer. GSK has steadfastly denied that Zantac causes cancer, pointing to the lack of any reliable evidence ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Based on the data collected, dental staff can now offer improved recommendations to ... The material science-based study carried out on behalf of GSK Consumer Healthcare (since renamed Haleon) was ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

GlaxoSmithKline (GSK) is a global biopharmaceutical company that focuses on the development and marketing of medicines, vaccines, and healthcare products, with a strong emphasis on innovation in ...

The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. The ongoing phase 1b/2a study is ...